Hyperbaric oxygen treatment

PreclinicalSmall molecule

Hyperbaric oxygen treatment is one of 29 small molecule programs targeting Wound Healing. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Wound HealingActive, not recruiting

Wound HealingPreclinical

Active, not recruiting

Competition

Competitive Landscape

133 competitors in Wound Healing

#DrugCompanyPhaseTrials

Avastin

BBio-Thera Solutions

Phase 3

1 2

Januvia

ZZydus Therapeutics Inc.

Phase 3

1 3

Glucophage

EMD Serono

Phase 3

1 4

Inderal

WWyeth-Lederle Vaccines

Phase 3

1 5

Growth Hormone

Pfizer

Phase 3

1 6

Vaseline

MMassachusetts General Hospital

Phase 3

1 7

Oxandrolone

PPar Pharmaceutical, Inc.

Phase 3

1 8

Becaplermin

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

1 9

Oxandrolone and Propranolol

TThe University of Texas Medical Branch, Galveston

Phase 3

1 10

Nicorette

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2033

Post-ApprovalNot yet recruiting

Clinical Trial

NCT07489274

Clinical

Trials by Indication[1]

Wound Healing1 trial

Effects of Hyperbaric Oxygen Therapy on Surgical Wound Healing

Unknown status·RRestorix Research Institute, LLLP·N/A·NCT01605110·164 enrolled

Clinical Trial1 trial

Adjunctive Hyperbaric Oxygen Treatment for Patients With Necrotizing Soft-Tissue Infection (HOT-NSTI Trial). Investigator-initiated, International, Multicentre, Superiority, Randomized, Open-label, Clinical Trial.

Not yet recruiting·OOle Hyldegaard·Phase 4·NCT07489274·1,480 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Hyperbaric oxygen treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hyperbaric oxygen treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hyperbaric oxygen treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Restorix Research Institute, LLLP company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: RRestorix Research Institute, LLLP

Hyperbaric oxygen treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2033

Trials by Indication[1]

Wound Healing1 trial

Clinical Trial1 trial

References

Drug Info

Quick Facts

Related News